IONIS-GCCRRx
Подписчиков: 0, рейтинг: 0
| Clinical data | |
|---|---|
| Other names | ISIS-426115; ISIS-GCCRRx |
| Drug class | Antiglucocorticoid |
| Identifiers | |
| UNII | |
IONIS-GCCRRx, also known as ISIS-426115, is an antiglucocorticoid which is under development by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) for the treatment of diabetes mellitus type 2. It has also been under investigation for the treatment of Cushing's syndrome, but no development has been reported. The drug is an antisense oligonucleotide against the glucocorticoid receptor. As of December 2017, it is in phase II clinical trials for diabetes mellitus type 2.